Chronic pelvic pain, quality of life and sexual health of women treated with palmitoylethanolamide and alpha-lipoic acid
Open-label, no control groupHumansWith alpha-lipoic acid
This study tested palmitoylethanolamide together with alpha-lipoic acid. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Open-label, no control group
- Subjects
- 56 women with endometriosis-associated pelvic pain
- Dose used in the study
- PEA 300 mg plus alpha-lipoic acid 300 mg twice daily
- Duration
- 9 months, assessed at 3, 6 and 9 months
- What was measured
- Pain VAS, SF-36 quality of life, Female Sexual Function Index, Female Sexual Distress Scale; PEA 300 mg + alpha-lipoic acid 300 mg twice daily
What the authors reported
No change in pain, quality of life or sexual function at 3 months. By 6 and 9 months, pain and all quality-of-life categories improved (p < 0.001). The sexual function and distress scores (FSFI, FSDS) are reported as improved from baseline (p < 0.001), but the abstract names the 3rd and 9th months for this, which conflicts with its own 3-month result.
Limits of this study
No control group, no blinding. Nine months is long enough for other treatments and the natural course to change symptoms. Two compounds combined. Funding not stated in the abstract.
Source
Entry checked against the abstract on PubMed on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.